Published in Cancer Res on October 15, 2004
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol (2012) 1.65
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos (2008) 1.46
Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets (2011) 1.35
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer (2011) 1.30
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25
New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther (2007) 1.18
Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett (2012) 1.16
EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. Br J Cancer (2008) 1.13
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol (2008) 1.12
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs (2010) 1.09
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol (2009) 1.09
The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol (2011) 1.06
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br J Pharmacol (2007) 1.03
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res (2010) 1.00
Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res (2009) 0.99
The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep (2009) 0.96
Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers (Basel) (2014) 0.95
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol (2009) 0.94
Interaction of innovative small molecule drugs used for cancer therapy with drug transporters. Br J Pharmacol (2012) 0.90
HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol (2010) 0.90
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest New Drugs (2011) 0.89
Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol Pharm (2011) 0.88
Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo. Neuro Oncol (2008) 0.88
Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma? Cancer Res Treat (2012) 0.87
Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem Pharmacol (2012) 0.86
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.85
Combination therapy with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with adrenal neuroblastoma. Cancer Med (2013) 0.84
Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions. Sarcoma (2011) 0.83
Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis. Adv Pharmacol Sci (2010) 0.82
MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem Pharmacol (2011) 0.81
Differential expression of ABC transporters (MDR1, MRP1, BCRP) in developing human embryos. J Mol Histol (2011) 0.81
Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic Clin Pharmacol Toxicol (2008) 0.81
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines. PLoS One (2015) 0.81
Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors. Pharmaceutics (2011) 0.80
Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? Clin Sarcoma Res (2015) 0.79
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol (2014) 0.78
Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. Oncotarget (2015) 0.78
Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. Br J Cancer (2011) 0.78
A new strategy to rapidly evaluate kinetics of glucuronide efflux by breast cancer resistance protein (BCRP/ABCG2). Pharm Res (2012) 0.77
Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Lett (2017) 0.75
CPT21, a novel compound with anti-proliferative effect against gastric cancer cell SGC7901. Invest New Drugs (2008) 0.75
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med (2011) 4.51
The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem (2004) 3.10
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A (2002) 2.74
Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol (2010) 2.63
Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc (2007) 2.54
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37
Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 2.31
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29
Identification of a mammalian mitochondrial porphyrin transporter. Nature (2006) 2.28
mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell (2010) 2.27
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25
Acetylcholinesterase inhibitors from plants. Phytomedicine (2007) 2.25
Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol (2012) 2.25
Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol (2003) 2.24
Leads from Indian medicinal plants with hypoglycemic potentials. J Ethnopharmacol (2006) 2.21
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
The brain tumor microenvironment. Glia (2011) 2.13
Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12
The feasibility and outcome of nephron-sparing surgery for children with bilateral Wilms tumor. The St Jude Children's Research Hospital experience: 1999-2006. Cancer (2008) 2.08
Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol (2004) 1.93
Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell (2004) 1.91
Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell (2007) 1.89
IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta (2006) 1.88
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol (2005) 1.85
Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell (2003) 1.84
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res (2005) 1.83
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res (2009) 1.79
Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol (2014) 1.78
Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release (2013) 1.77
Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol (2006) 1.75
Siah regulation of Pard3A controls neuronal cell adhesion during germinal zone exit. Science (2010) 1.74
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71
The immediate impact of different types of television on young children's executive function. Pediatrics (2011) 1.69
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol (2004) 1.67
Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.66
The brain tumor microenvironment. Glia (2012) 1.66
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther (2007) 1.64
Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res (2003) 1.63
Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem (2002) 1.61
Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol (2007) 1.61
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol (2011) 1.60
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res (2006) 1.58
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J (2003) 1.57
Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology (2006) 1.54
Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J (2005) 1.53
Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs (2002) 1.52
Retracted FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol (2005) 1.51
Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics (2003) 1.51
The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol Ther (2007) 1.50
Expression of the pregnane X receptor in mice antagonizes the cholic acid-mediated changes in plasma lipoprotein profile. Arterioscler Thromb Vasc Biol (2005) 1.49
Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav (2003) 1.48
The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metab (2014) 1.47
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res (2004) 1.47
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (2010) 1.47
Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem (2004) 1.46
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest (2005) 1.46
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther (2011) 1.45
Deficiency of ATP-binding cassette transporter B6 in megakaryocyte progenitors accelerates atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2014) 1.45
A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol (2012) 1.44
Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma. Pediatr Blood Cancer (2013) 1.41
Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem (2005) 1.41
Improving the histopathologic diagnosis of pediatric malignancies in a low-resource setting by combining focused training and telepathology strategies. Pediatr Blood Cancer (2012) 1.39
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol (2006) 1.38
In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med (2008) 1.37
4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem (2002) 1.37
Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem (2004) 1.37
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res (2007) 1.35
Antioxidant activity of methanol extracts obtained from Plantago species. J Agric Food Chem (2005) 1.32
Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther (2006) 1.32
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol (2011) 1.30
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Stat Med (2003) 1.30
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol (2009) 1.29
Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther (2007) 1.28
Metastatic osteosarcoma. Cancer (2006) 1.27
In vitro cytotoxic activity of Thai medicinal plants used traditionally to treat cancer. J Ethnopharmacol (2004) 1.27
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models. Biometrics (2002) 1.26
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res (2004) 1.26
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.26
Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res (2003) 1.26
Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. Cancer Res (2003) 1.26